Article

2018 FDA Advancements in Small Lymphocytic Leukemia

Author(s):

Brielle Benyon

Take a look at the FDA’s decisions for the treatment of SLL that happened this year.

The year 2018 was a busy one for the Food and Drug Administration (FDA) when it came to actions in the blood cancer space. There were three major advancements for the treatment of patients with small lymphocytic leukemia (SLL):

  • Venclexta plus Rituxan. This combination was approved in June for patients with SLL — as well as chronic lymphocytic leukemia (CLL) – who have already had at least one other form of treatment. The drugs are given intravenously, and the combination is approved to treat patients regardless of whether or not they have a 17p deletion.
  • Copiktra: In September, Copiktra (duvelisib) was granted FDA approval for patients with relapsed or refractory SLL or CLL who previously underwent two or more treatment options. Unlike Venclexta and Rituxan, Copiktra is given in pill form.
  • Imbruvica plus Gazyva. The drug combination Imbruvica (ibrutinib) plus Gazyva (obinutizumab) was granted priority review in October, meaning that the FDA will review and potentially approve the regimen in six months instead of the usual 10. If approved, the duo will be used to treat patients in the frontline setting.
Related Content
Illustration of a woman with curly red hair.
October 2nd 2024

Cancer Makes Me Look at Life Differently

Linda Cohen
After recently losing my aunt, I realized that cancer has given me a new perspective on life, which reminds me that every day has meaning.
Illustration of CLL cells.
September 17th 2024

Treatment Switching May Be Less Likely With Brukinsa vs Other BTK Inhibitors in CLL/SLL

Jax DiEugenio
Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic lymphocytic leukemia.
Illustration of a woman with red curly hair.
September 2nd 2024

10 Lessons I Learned from 15 Years With Chronic SLL

Linda Cohen
Living with chronic small lymphocytic lymphoma for the past 15 years has taught me some very valuable lessons, from dieting to managing anxiety.
Illustration of chronic lymphocytic leukemia cells.
August 26th 2024

FDA Fast Tracks BGB-16673 for CLL, SLL

Brielle Benyon
The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.
Illustration of a woman with curly red hair.
July 17th 2024

Finding Focus Outside of My Cancer

Linda Cohen
After having SLL for 15 years, I won't let it define me — now, I'm working towards larger passions in my life.
Image of small lymphocytic leukemia.
June 18th 2024

Calquence, Brukinsa Outperform Imbruvica in CLL/SLL Treatment

Kyle Doherty
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma tended to be more likely to stay on treatment and experience fewer heart toxicities with Calquence or Brukinsa.